Evaluating dopamine transporter imaging as an enrichment biomarker in a phase 2 Parkinson’s disease trial

por R. Matthew Hutchison, Karleyton C. Evans, Tara Fox, Minhua Yang, Jerome Barakos, Barry J. Bedell, Jesse M. Cedarbaum, Miroslaw Brys, Andrew Siderowf, Anthony E. Lang
Publicado 2021

Biomarkers of neurodegeneration and glial activation validated in Alzheimer's disease assessed in longitudinal cerebrospinal fluid samples of Parkinson's disease.

por Michael Bartl, Mohammed Dakna, Douglas Galasko, Samantha J Hutten, Tatiana Foroud, Marian Quan, Kenneth Marek, Andrew Siderowf, Jonas Franz, Claudia Trenkwalder, Brit Mollenhauer, Parkinson’s Progression Markers Initiative
Publicado 2021